No difference in overall survival reported in phase III TIVO-1 study of tivozanib vs. sorafenib for advanced renal cell carcinoma

Source: BioSpace Area: News AVEO Oncology and Astellas Pharma Inc. have announced overall survival (OS) data (secondary endpoint) for tivozanib, an oral, once-daily, investigational tyrosine kinase inhibitor, from the phase III TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final analysis shows a median OS of 28.8 months (95% CI: 22.5-NA) for tivozanib vs. 29.3 months (29.3 to NA) for the comparator arm, sorafenib. No statistical difference between the two arms (hazard ratio 1.245, p=0.105) was observed.   TIVO-1 is a global, randomised phase III superiority trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced RCC. Tivozanib demonstrated a statistically significant improvement in progression-free survival, the primary endpoint of the study, when compared with sorafenib (12.7 months vs. 9.1 months; hazard ratio 0.756, p=0.0371).   The OS ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news